Back to Newsroom

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

SAN FRANCISCO, Feb. 6, 2018​ – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced topline results from the MODIFY2 Phase 2 clinical trial of SB-061 for symptom management in mild-to-moderate osteoarthritis of the knee. The 12-week, multicenter, double-blind trial of 60 patients was designed to investigate the effects of SB-061 in the overall population as well as a prespecified subpopulation of patients with knee effusions.